WCM/EADO 2021 | Understanding the clinical context for OX40 agonists in melanoma
Jedd Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, describes recent preclinical research aiming to improve the understanding of how best to incorporate anti-OX40 antibodies into therapeutic strategies for melanoma and overcome the challenge of intra-tumoral antigenic heterogeneity associated with a range of immunotherapeutic interventions. Research in mouse models has demonstrated that treatment with anti-OX40 antibodies alongside the infusion of T cell receptor (TCR) transgenic T cells can enhance bystander tumor killing activity through the recruitment of neutrophils and overcome heterogeneity of target antigen expression. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.
Disclosures
Jedd Wolchok, MD, PhD has participated in consultancy work for Adaptive Biotech, Amgen, Apricity, Ascentage Pharma, Arsenal IO, Astellas, AstraZeneca, Bayer, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Daiichi Sankyo, Dragonfly, Eli Lilly, Elucida, F Star, Georgiamune, Idera, Imvaq, Kyowa Hakko Kirin, Linneaus, Maverick Therapeutics, Merck, Neon Therapeutics, Polynoma, Psioxus, Recepta, Takara Bio, Trieza, Truvax, Trishula, Sellas, Serametrix, Surface Oncology, Syndax, Syntalogic and Werewolf Therapeutics; has received grant/research support from Bristol Myers Squibb and Sephora; and is an equity holder of Tizona Pharmaceuticals, Adaptive Biotechnologies, Imvaq, Beigene, Linneaus, Apricity, Arsenal IO and Georgiamune.
